Inactivation and removal of prions in the processing of medical devices: A contribution to the examination and declaration of suitable methods;Inaktivierung und Entfernung von Prionen bei der Aufbereitung von Medizinprodukten: Ein Beitrag zur Prüfung und Deklaration geeigneter Verfahren

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 47, Issue 1, 2004, Pages 36-40

  Bertram, J ^a   Mielke, M ^a   Beekes, M ^a   Lemmer, K ^a   Baier, M ^a   Pauli, G ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; CREUTZFELDT JAKOB DISEASE; CROSS INFECTION; DISEASE TRANSMISSION; DISINFECTION; DRUG CONTAMINATION; HEATING; HUMAN; INSTRUMENT STERILIZATION; METHODOLOGY; PATHOGENICITY; PRION; SURGICAL INSTRUMENT; VIROLOGY; VIRULENCE; VIRUS INACTIVATION;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; CROSS INFECTION; DISINFECTION; DRUG CONTAMINATION; HEATING; HUMANS; PRIONS; STERILIZATION; SURGICAL INSTRUMENTS; VIRULENCE; VIRUS INACTIVATION;

EID: 30444435231     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-003-0761-8     Document Type: Note

References (64)

1. Abschlussbericht der Task Force vCJK (2002) Die Variante der Creutzfeldt-Jakob-Krankheit (vCJK). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 45: 376-394
2. McDonnell G, Burke P (2003) The challenge of prion decontamination. CID 36: 1152-1154
3. RKI-Mitteilung (1998) Krankenversorgung und Instrumentensterilisation bei CJK-Patienten und CJK-Verdachtsfällen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 41: 279-285
4. Empfehlungen der Kommission für Krankenhaushygiene und Infektionsprävention (2001) Anforderungen an die Hygiene bei der Aufbereitung von Medizinprodukten. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44: 1115-1126
5. Informationen zu CJK/vCJK, http://www.rki.de,dort Link zu Gesundheit und Krankheiten, weiterer Link zur Krankenhaushygiene
6. Beekes M, Mielke M, Kurth R (2002) Aspekte zur Risikoabschätzung und Prävention noso-komialer Übertragungen der klassischen und varianten Creutzfeldt-Jakob-Krankheit. Internist 43: 738, 741-748
7. Beekes M, Mielke M, Pauli G et al.(in press) Aspects of risk assessment and risk management of nosocomial transmission of classical and variant Creutzfeldt-Jakob disease with special attention to German regulations. In: Rabenau HF, Cinatl J, Doerr HW (eds) Prions. A Challenge for science, medicine and public health system. 2nd, revised edition. Contrib Microb, vol 11. Basel, Karger, pp 117-135
8. Asante EA et al.(2002) BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 21: 6358-6366
9. Butler D (2002) Prion data suggest BSE link to sporadic CJD. Nature 420: 450
10. http://www.bag.admin.ch/prionen/d/verordn.d.pdf
11. Taguchi F et al. (1991) Proposal for a procedure for complete inactivation of the Creutzfeld-Jakob disease agent. Arch Virol 119: 297-301
12. Ernst DR, Race RE (1993) Comparative analysis of scrapie agent inactivation methods. J Virol Methods 41: 193-202
13. Appel TR et al.(2001) Heat stability of prion rods and recombinant prion protein in water, lipid and lipid-water mixtures. J Gen Virol 82: 465-473
14. Taylor DM, McConnell I, Fernie K (1996) The effect of dry heat on the ME7 strain of mouse-passaged scrapie agent. J Gen Virol 77: 3161-3164
15. Taylor DM (1999) Inactivation of prions by physical and chemical means. J Hosp Infect 43 [Suppl]: S69-S76
16. WHO (1999) Infection control guidelines for transmissible spongiform encephalopathies. Report of a WHO Consultation, Geneva, Switzerland, 23-26 March 1999 (WHO/CDS/CSR/APH/2000.3); http://www.who.int/emc-documents/tse/whocdscs- raph2003c.html, link PDF/english
17. Iffenecker A, Ruef C (2002) Übertragungsrisiko von Prionen: Stellungnahme zur Aufbereitung thermostabiler chirurgischer Instrumente vor der Sterilisation. Swiss NOSO 9: 25-28
18. Rutala WA, Weber DJ (2001) Creutzfeldt-Jakob disease: recommendations for disinfection and sterilisation. Clin Infect Dis 32: 1348-1356
19. Bloß R (2002) Einfluss der Desinfektionswirkstoffe auf die Instrumentenreinigung. http://www.bode-chemie,Link zu Service/ Publikationen/Instrumentenaufbereitung
20. Taylor DM (2000) Inactivation of transmissible degenerative encephalopathy agents: a review. Vet J 159: 10-17
21. Taylor DM et al.(1994) Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 139: 313-326
22. Shenoy VN, Revak TT (1998) Prion inactivation in connective tissue materials. Off Gaz US Patent Trademark off pat 1210: 3648
23. Reichl H (1997) Methods of inactivating prions (slow viruses) conventional viruses and other infections agents in biological material. Off Gaz US Patent Trademark off pat 1198: 2591
24. Prusiner SB et al.(1993) Attempts to restore scrapie prion infectivity after exposure to protein denaturants. Proc Nat Acad Sci 90: 2793-2797
25. Chartier V et al. (2001) Experimental results of detergent and pre-disinfection treatments before sterilisation of medical devices. Zentralsterilisation 9: 100-107
26. Antloga K et al. (2000) Prion disease and medical devices. ASAIO 46: 69-72
27. Yamamoto M et al.(2001) Glycidol degrades scrapie mouse prion protein. J Vet Med Sci 63: 983-990
28. Hörnlimann B, Leutwiler A, Oberthür RC, Widmer HR (2001) Die chemische Desinfektion und Inaktivierung von Prionen. In: Hörnlimann B, Riesner D, Kretzschmar H (Hrsg) Prionen und Prionkrankheiten. de Gruyter, Berlin-New York, S 381-388, 389
29. Zobeley E et al. (1999) Infectivity of scrapie prions bound to a stainless steel surface. Mol Med 5: 240-243
30. Flechsig E et al.(2001) Transmission of scrapie by steel-surface-bound prions. Mol Med 7: 679-684
31. Kimberlin RH, Walker CA (1986) Pathogenesis of scrapie (strain 263 K) in hamsters infected intracerebrally, intraperitoneally or intra-ocularly. J Gen Virol 67: 255-263
32. Kimberlin RH, Walker CA (1977) Characteristics of a short incubation model of scrapie in the golden hamster. J Gen Virol 34: 295-304
33. Prusiner SB et al. (1982) Measurement of the scrapie agent using an incubation time interval assay. Ann Neurol 11: 353-358
34. Sc sensitive to proteinase K.J Gen Virol 84: 3173-3176
35. Sc. In: International Prion Conference "Prion Diseases: from basic research to intervention concepts"; München, 8.10.-10.10.2003: Abstract IV-02
36. Sharma CP, Chandy T (1987) Influence of L-ascorbic acid, blood cells and components on protein adsorption/desorption on polycarbonate. Haemostasis 17: 70-78
37. Williams DF, Askill IN, Smith R (1985) Protein absorption and desorption phenomena on clean metal surfaces. J Biomed Mat Res 19: 313-320
38. Biswas SC, Chattoraj DK (2002) Kinetics of desorption of preadsorbed proteins from the surface of silica and charcoal by various desorbing reagents.http://preprint.chemweb.com/chemeng/0206003
39. Narhi LO et al.(1997) Fractionating and characterization of polyclonal antibodies using three progressively more chaotropic solvents. Anal Biochem 253: 246-252
40. Washabaugh MW, Collins KD (1986) The systematic characterization by aqueous column chromatography of solutes which affect protein stability. J Biol Chem 261: 12477-12485
41. Stöckel J, Hartl FU (2001) Chaperonin-mediat-ed de novo generation of prion protein aggregates. J Mol Biol 313: 861-872
42. DebBurman SK, Lindquist S (2000) Chaperone-promoted solubilization of protease-resistant prion protein. FASEB J 14: 425
43. Hjelmeland LM (1990) Solubilization of native membrane proteins. Meth Enzym 182: 253-264
44. Xiong LW et al.(2001) Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J Neurochem 79: 669-679
45. Herbert B (1999) Advances in protein solubi-lisation for two-dimensional electrophoresis. Electrophoresis 20: 660-663
46. Fountoulakis M, Takacs B (2001) Effect of strong detergents and chaotropes on the detection of proteins in two-dimensional gels. Elektrophoresis 22: 1593-1602
47. König S, Schmidt O, Rose K et al.(2003) Sodium dodecyl sulfate versus acid-labile surfactant gel electrophoresis: comparative proteomic studies on rat retina and mouse brain. Electrophoresis 24: 751-756
48. Ross ARS et al. (2002) Identification of proteins from two-dimensional polyacrylamide gels using a novel acid-labile surfactant. Proteomics 2: 928-936
49. Chevallet M et al. (1998) New zwitterionic detergents improve the analysis of membrane proteins by two-dimensional electrophoresis. Electrophoresis 19: 1901-1909
50. Arbab ME, Tinay AH (1997) Effect of cooking and treatment with sodium bisulphite or ascorbic acid on the in vitro protein digestibilty of two sorghum cultivars. Food Chem 59: 339-343
51. Sc in natural sheep scrapie. Arch Virol 142: 1603-1612
52. Warwicker J, Cole C (2001) The structural and spectroscopic basis for modelling prion protein interactions. Spectroscopy 15: 151-159
53. Herrmann LM, Caughey B (1998) The importance of the disulfide bond in prion protein conversion. Neuroreport 9: 2457-2461
54. Brown DR, Clive C, Haswell SJ (2001) Anti-oxidant activity related to copper binding of native prion protein. J Neurochem 76: 69
55. Feughelman M, Willis B (2002) Potential involvement of copper and thiol-disulphide interchange in prion proteins' conformational conversion. Medical Hypotheses 59: 321
56. Martins V, Brentani R (2002) The biology of the cellular prion protein. Neurochem Int 41: 353
57. Callahan MA, Xiong L, Caughey B (2001) Reversability of scrapie-associated prion protein aggregation. J Biol Chem 276: 28022-28028
58. Lee DC et al. (2001) A direct relationship between the partitioning of the pathogenic pri-on protein and transmissible spongiform ence-phalopathy infectivity during the purification of plasma proteins. Transfusion 41: 449-455
59. PL976065: Inactivation of the causative agents of transmissible spongiform encephalopathies by thermophilic and hyperthermophilic proteases.http://tse-ip.org/eu-projects/p 1976065-eu-tse-project.shtml
60. http://www.newscientist.com/news/news.jsp?id=ns99993999 29 July 03
61. Prusiner BS, Safar JG (2001) Removal of prions from blood, plasma and other liquids contacting with a solid substrate comprising a complexing agent such as sodium phosphotungs-tate to bind Prions in the sample, separating sample from the substrate. US Patent 6221614
62. Forloni G et al.(2002) Tetracyclines affect prion infectivity. PNAS 99: 10849
63. Demaimey R, Chesebro B, Caughey B (2000) Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogs. Arch Virol Suppl 16: 277
64. Soto C et al.(2000) Reversion of prion protein conformational changes by synthetic betasheet breaker peptides. Lancet 355: 192-197